Vaxxinity, Inc.

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Dallas, TX.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.

DALLAS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the closing of its initial public offering of 6,000,000 shares of class A common stock at a public offering price of $13.00 per share on November 15, 2021 as well as the subsequent closing on November 18, 2021 of the issuance of an additional 537,711 shares of class A common stock, pursuant to a 30-day option granted to the underwriters to purchase up to an additional 900,000 shares of class A common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering and the partial exercise of the underwriters' option to purchase additional shares of class A common stock, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxxinity, were approximately $85.0 million. Vaxxinity's class A common stock began trading on The Nasdaq Global Market on November 11, 2021, under the ticker symbol “VAXX.” All shares in the offering were offered by Vaxxinity.

Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters' Option to Purchase Additional Shares

Shares of VAXX stock are trading higher today after last week's public debut. Could its Covid-19 vaccine candidate send shares even higher?

VAXX Stock Alert: 10 Things to Know About Newly Public Vaxxinity as Shares Soar

Vaxxinity Inc. VAXX, +19.23% started its public life with a big rally, as the Texas-based biotechnology company's stock was trading more 21.2% above its initial public offering price. The company said overnight that its IPO of 6.0 million shares, down from previous expectations of a 6.7-million share offering, priced at $13 a share, below the expected range of between $14 and $16 a share.

Vaxxinity enjoys warm Wall Street reception as stock trades 20% above IPO price

DALLAS, Texas, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the pricing of its initial public offering of 6,000,000 shares of class A common stock at a public offering price of $13.00 per share. In addition, Vaxxinity has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of class A common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of class A common stock are being offered by Vaxxinity. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxxinity, assuming the underwriters fully exercise their over-allotment option, are expected to be $89.7 million. Vaxxinity's class A common stock is expected to begin trading on The Nasdaq Global Market on November 11, 2021, under the ticker symbol “VAXX.” The offering is expected to close on November 15, 2021, subject to the satisfaction of customary closing conditions.

Vaxxinity Announces Pricing of Initial Public Offering

News for Vaxxinity, Inc. Stock (VAXX)